Investing.com - Incyte (NASDAQ:INCY) reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Incyte announced earnings per share of $0.82 on revenue of $813M. Analysts polled by Investing.com anticipated EPS of $0.574 on revenue of $739.09M.
Incyte shares are down 2% from the beginning of the year, still down 31.65% from its 52 week high of $101.47 set on January 25. They are under-performing the Nasdaq which is up 21.01% from the start of the year.
Incyte follows other major Healthcare sector earnings this month
Incyte's report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Thermo Fisher Scientific had beat expectations on October 27 with third quarter EPS of $5.76 on revenue of $9.33B, compared to forecast for EPS of $4.68 on revenue of $8.38B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar